Handelsinvest Investeringsforvaltning Lowers Stake in Repligen Co. (NASDAQ:RGEN)

Handelsinvest Investeringsforvaltning reduced its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 34.2% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 1,434 shares of the biotechnology company’s stock after selling 745 shares during the period. Handelsinvest Investeringsforvaltning’s holdings in Repligen were worth $264,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in RGEN. Norges Bank acquired a new stake in shares of Repligen in the 4th quarter worth $48,208,000. Artemis Investment Management LLP acquired a new stake in shares of Repligen in the fourth quarter valued at about $22,552,000. American Century Companies Inc. lifted its stake in shares of Repligen by 97.5% in the third quarter. American Century Companies Inc. now owns 217,900 shares of the biotechnology company’s stock valued at $34,648,000 after purchasing an additional 107,570 shares during the period. Comerica Bank lifted its stake in shares of Repligen by 1,259.1% in the third quarter. Comerica Bank now owns 115,929 shares of the biotechnology company’s stock valued at $18,434,000 after purchasing an additional 107,399 shares during the period. Finally, Public Employees Retirement Association of Colorado lifted its stake in shares of Repligen by 448.0% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 112,863 shares of the biotechnology company’s stock valued at $20,293,000 after purchasing an additional 92,268 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Transactions at Repligen

In other news, CEO Anthony Hunt sold 20,072 shares of Repligen stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the completion of the sale, the chief executive officer now directly owns 163,177 shares in the company, valued at $27,456,162.02. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Anthony Hunt sold 20,072 shares of the business’s stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total value of $3,377,314.72. Following the completion of the sale, the chief executive officer now directly owns 163,177 shares in the company, valued at $27,456,162.02. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Martin D. Madaus bought 1,615 shares of the stock in a transaction that occurred on Friday, June 14th. The stock was bought at an average price of $124.94 per share, with a total value of $201,778.10. Following the completion of the acquisition, the director now owns 4,613 shares of the company’s stock, valued at approximately $576,348.22. The disclosure for this purchase can be found here. Insiders own 1.20% of the company’s stock.

Analyst Ratings Changes

RGEN has been the subject of several recent analyst reports. Guggenheim initiated coverage on shares of Repligen in a research note on Tuesday, June 18th. They issued a “neutral” rating for the company. Deutsche Bank Aktiengesellschaft upgraded shares of Repligen from a “hold” rating to a “buy” rating and reduced their price objective for the company from $180.00 to $155.00 in a research note on Wednesday, June 26th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $193.00.

Repligen Price Performance

NASDAQ:RGEN traded up $3.01 during mid-day trading on Wednesday, hitting $123.15. 36,520 shares of the company’s stock traded hands, compared to its average volume of 589,919. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.24 and a current ratio of 6.35. The firm’s 50 day simple moving average is $150.00 and its 200 day simple moving average is $173.10. Repligen Co. has a 1 year low of $110.45 and a 1 year high of $211.13. The company has a market cap of $6.88 billion, a PE ratio of 480.58, a price-to-earnings-growth ratio of 4.22 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). The firm had revenue of $151.31 million for the quarter, compared to analysts’ expectations of $150.06 million. Repligen had a return on equity of 3.95% and a net margin of 2.44%. The business’s quarterly revenue was down 17.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.64 earnings per share. Sell-side analysts expect that Repligen Co. will post 1.46 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.